Acute Leukemias: Mastering the Latest Developments in the Absence of Targetable Mutations

Download All
Gain insights into the latest advances in the use of new approaches for treating patients with ALL and AML, including biomarkers, new targeted agents, safety considerations, and clinical trials, through expert-guided discussion and case-based examples.
Stéphane de Botton, MD
David Marks, MD, PhD

Downloadable Slidesets

Download this short slideset of key takeaways from a live CCO Webinar focused on the latest developments in acute leukemias.

Stéphane de Botton, MD David Marks, MD, PhD Released: July 14, 2020

Download these slides to review expert insights on optimizing treatment for patients with ALL.

David Marks, MD, PhD Released: July 10, 2020

Download these slides to review expert insights on the latest developments in the treatment of patients with AML

Stéphane de Botton, MD Released: July 10, 2020

On-Demand Webcast

Watch this on-demand Webcast capturing a live CCO Webinar featuring expert presentations on optimizing treatment for patients with acute leukemias.

Stéphane de Botton, MD David Marks, MD, PhD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: October 7, 2020 Expired: October 6, 2021

ClinicalThought

Here’s my take on how patient-specific factors and ultimate treatment goals direct selection of therapy for patients with R/R ALL.

David Marks, MD, PhD Released: September 30, 2020

Podcast

Listen as David Marks, MD, PhD, and Stéphane de Botton, MD, answer questions from clinicians on management pearls for patients with acute leukemias.

Stéphane de Botton, MD David Marks, MD, PhD Released: October 2, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Pfizer Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue